Shell Asset Management Co. Makes New Investment in BioNTech SE (NASDAQ:BNTX)

Shell Asset Management Co. acquired a new position in shares of BioNTech SE (NASDAQ:BNTX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 19,440 shares of the company's stock, valued at approximately $2,215,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its stake in BioNTech by 110.3% in the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after acquiring an additional 246 shares during the period. Quintet Private Bank Europe S.A. raised its holdings in BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock worth $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE bought a new stake in BioNTech during the fourth quarter worth approximately $90,000. Generali Investments CEE investicni spolecnost a.s. bought a new stake in BioNTech during the fourth quarter worth approximately $137,000. Finally, AlphaCentric Advisors LLC bought a new position in shares of BioNTech in the fourth quarter valued at $168,000. Institutional investors and hedge funds own 15.52% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have issued reports on BNTX shares. Morgan Stanley dropped their price target on BioNTech from $140.00 to $132.00 and set an "overweight" rating on the stock in a report on Tuesday, May 6th. BMO Capital Markets upped their price objective on shares of BioNTech from $130.00 to $143.00 and gave the stock an "outperform" rating in a report on Tuesday, March 11th. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. HC Wainwright reissued a "buy" rating and issued a $134.00 price objective (down from $145.00) on shares of BioNTech in a research note on Wednesday, May 14th. Finally, Citigroup restated a "buy" rating and issued a $140.00 target price (down from $145.00) on shares of BioNTech in a report on Tuesday, May 6th. Three investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, BioNTech has a consensus rating of "Moderate Buy" and a consensus target price of $142.08.

BioNTech Price Performance

Shares of BNTX traded up $3.92 during mid-day trading on Tuesday, hitting $101.72. 1,812,605 shares of the company traded hands, compared to its average volume of 937,789. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The company has a current ratio of 7.33, a quick ratio of 7.21 and a debt-to-equity ratio of 0.01. The business has a 50-day moving average of $97.36 and a 200 day moving average of $108.72. The stock has a market capitalization of $24.45 billion, a price-to-earnings ratio of -48.44 and a beta of 1.35.

BioNTech (NASDAQ:BNTX - Get Free Report) last released its quarterly earnings results on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating the consensus estimate of $0.38 by $0.70. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The business had revenue of $1.19 billion for the quarter, compared to analysts' expectations of $1.24 billion. During the same period in the prior year, the firm earned $1.90 earnings per share. BioNTech's revenue was down 19.5% compared to the same quarter last year. As a group, equities analysts expect that BioNTech SE will post -3.88 earnings per share for the current fiscal year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.